2. Academic Validation
  3. Combination of Ginsenoside Compound K and Anti-PD1 Inhibits Pancreatic Cancer by Activating CXCL13-CXCR5 Signaling Axis

Combination of Ginsenoside Compound K and Anti-PD1 Inhibits Pancreatic Cancer by Activating CXCL13-CXCR5 Signaling Axis

  • J Agric Food Chem. 2025 Jun 18;73(24):15125-15137. doi: 10.1021/acs.jafc.5c01821.
Shiyan Shang 1,  Haixia Yang 2,  Daidi Fan 1,  Jianjun Deng 1 3
Affiliations

Affiliations

  • 1 Shaanxi Key Laboratory of Degradable Biomedical Materials, Shaanxi R&D Center of Biomaterials and Fermentation Engineering, Biotech & Biomed Research Institute, School of Chemical Engineering, Northwest University, Xi'an 710069, China.
  • 2 College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, China.
  • 3 State Key Laboratory of Vegetable Biobreeding, Institute of Vegetables and Flowers, Chinese Academy of Agricultural Sciences, Beijing 100081, China.
PMID: 40474585 DOI: 10.1021/acs.jafc.5c01821
Abstract

Pancreatic Cancer is a highly malignant tumor with a poor prognosis, making it a leading cause of cancer-related deaths. While immune checkpoint inhibitors (ICIs) have shown efficacy in treating various solid tumors, their effectiveness in pancreatic Cancer is limited due to its unique tumor immune microenvironment (TIME). Thus, developing novel combination therapies is critical. Ginsenoside compound K (CK), a natural product with antitumor and immunomodulatory properties, holds the potential for combination therapy with ICIs. This study investigates the therapeutic effects of CK combined with Anti-PD1 inhibitors in a Panc02 tumor model. The combination therapy significantly improved survival, enhanced T-cell infiltration and activation, remodeled the tumor stroma by reducing Collagen I and α-SMA, and improved vasculature formation. RNA Sequencing revealed changes in genes associated with T-cell activation, chemokines, and angiogenesis. These findings suggest that CK combined with Anti-PD1 therapy offers a promising strategy for pancreatic Cancer treatment by modulating TIME and enhancing antitumor activity.

Keywords

anti-PD1; combination therapy; ginsenoside CK; pancreatic cancer.

Figures
Products